DOCKET NO.: 208888US0PCT



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

#10

IN RE APPLICATION OF:

Jean-Claude BEAUVILLIAN, et al.

: GROUP ART UNIT: 1636

SERIAL NO.: 09/831,907

FILED: SEPTEMBER 18, 2001 : EXAMINER: SULLIVAN

FOR: UROTENSINS II OF MAMMALS AND THEIR USES

RECEIVED

JAN 1 7 2003

RESPONSE TO RESTRICTION REQUIREMENT

TECH CENTER 1600/2900

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

SIR:

Responsive to the Official Action dated December 16, 2002, Applicants elect, with traverse, Group I, Claims 1, 2, 9, 10, 14 and 15, for further prosecution.

REMARKS

The Office has required restriction in the present application as follows:

Group I: Claims 1, 2, 9, 10, 14 and 15, drawn to a polypeptide comprising at its C-terminus the heptapeptide Cys-Phe-Trp-Lys-Tyr-Cys-Xaa, wherein Xaa represents Val or Ile, and having at least 45% similarity with the polypeptide sequence set forth as SEQ ID NO: 1, pharmaceutical compositions comprising the polypeptide and methods of using the polypeptide;

Group II: Claims 3-9 and 13, drawn to a purified nucleic acid fragment wherein said nucleic acid fragment constitutes at least an oligonucleotide derived from a fragment consisting of a sequence encoding a polypeptide of Group I or complement thereof, a vector, host cell and kit comprising said purified nucleic acid fragment, wherein said fragment a human sequence;

Group III: Claims 3-9 and 13, drawn to a purified nucleic acid fragment wherein said nucleic acid fragment constitutes at least an oligonucleotide derived from a fragment consisting of a sequence encoding a polypeptide of